Patient eligibility
infection, non-metastatic primary SCCAC
HEART DISEASE, INFECTION, METABOLIC DISORDERS, ONCOLOGY, MALIGNANT DISEASE
The JROSG 10–2 trial was a multicenter phase II study approved by the Japanese Radiation Oncology Study Group (JROSG) and the institutional review boards of all participating centers (representative institution approval date: September 9, 2013). Written informed consent was obtained from each patient before participating in the study. This study was registered in the Japan Registry of Clinical Trials under number jRCTs041180053.Patients aged 20–80 years with a histologically confirmed diagnosis of non-metastatic primary SCCAC (cT1–4, any N, M0 according to 7th edition of the UICC TNM classification) were eligible for enrollment. Additional eligibility criteria included a good general condition (Eastern Cooperative Oncology Group performance status 0 or 1) and normal liver, renal and bone marrow function. The exclusion criteria were as follows: (i) a history of malignant disease, (ii) severe heart disease, uncontrolled infection, or metabolic disorders, (iii) any prior pelvic irradiation, (iv) anti-HIV antibody positivity, (v) HBsAg positivity, and (vi) other cases judged inappropriate for this study by the attending doctor.